Intech Investment Management LLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Intech Investment Management LLC boosted its position in Thermo Fisher Scientific Inc. by 70.7% during the first quarter, owning a total of 13,926 shares valued at approximately $6.93 million.
• The company reported earnings of $5.36 per share in its latest quarter, exceeding analysts' expectations, with a revenue of $10.86 billion, marking a 2.9% year-over-year increase.
• Thermo Fisher has announced a quarterly dividend of $0.43 per share, with an annualized dividend yield of 0.4%, set to be paid on October 15th.

Intech Investment Management LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 70.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,926 shares of the medical research company's stock after buying an additional 5,769 shares during the period. Intech Investment Management LLC's holdings in Thermo Fisher Scientific were worth $6,930,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Brighton Jones LLC lifted its holdings in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after buying an additional 461 shares in the last quarter. Nomura Holdings Inc. lifted its holdings in Thermo Fisher Scientific by 179.1% during the 4th quarter. Nomura Holdings Inc. now owns 15,427 shares of the medical research company's stock valued at $8,026,000 after buying an additional 9,899 shares in the last quarter. Finally, MainStreet Investment Advisors LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $233,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 2.4%

Shares of NYSE:TMO traded down $11.93 during trading on Friday, reaching $479.48. The stock had a trading volume of 1,543,232 shares, compared to its average volume of 1,509,627. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a market capitalization of $181.06 billion, a P/E ratio of 27.73, a PEG ratio of 2.56 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm's 50-day simple moving average is $466.86 and its 200 day simple moving average is $451.08.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $490.00 to $550.00 in a research report on Thursday. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Raymond James Financial reissued an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Finally, Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $592.24.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last three months. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.